Background Role of obesity in renal pathological and structural changes remains poorly investigated, and this study was designed to examine the pathological effects of obesity on renal structural components in patients with chronic kidney diseases (CKD). Methods The study subjects were obese (body mass index, BMI C 25 kg/m 2 ) patients with nonglomerulonephritis (non-GN, n = 26), IgA nephropathy (IgAN, n = 19), benign nephrosclerosis (BNS, n = 15), and thin basement membrane disease (TMD, n = 6), and 65 nonobese controls (n = 20, 20, 10, and 15, respectively). Patients were evaluated for glomerular lesions (mesangial proliferation and focal segmental/global glomerulosclerosis), glomerular size, and thickness of glomerular basement membrane (GBM).
Introduction
Several studies have reported recently about the association between obesity and renal dysfunction [1] [2] [3] [4] [5] . Obesity should be placed high on the list of potentially preventable causes of chronic kidney disease (CKD) [6] . Clinical features of obese subjects without systemic disorders or apparent renal disorders, so-called obesity-related glomerulopathy (ORG), include slowly progressive proteinuria. Various structural changes, including glomerulomegaly, focal segmental glomerulosclerosis (FSGS), and thickening of the glomerular basement membrane (GBM) can be seen in biopsy sections of ORG [2, 3, 7] .
Glomerulomegaly is also observed in the kidneys of patients with diabetic nephropathy and hypertensive nephropathies [8] [9] [10] . The increase in glomerular volume is usually the consequence of glomerular hyperfiltration, and can be associated with expansion of the capillary loops [1, 11] . Obesity can accelerate renal dysfunction in patients with glomerulonephritis such as IgA nephropathy (IgAN). In fact, obese patients with IgAN exhibit more severe pathological changes and proteinuria [4] . However, there is only little information on the histopathological findings, especially ultrastructural changes, in obese patients with CKD.
The aim of this study was to examine the clinical and pathological effects of obesity in three types of CKD: IgAN, benign nephrosclerosis (BNS), and thin basement membrane disease (TMD), and to compare them with those seen in ORG.
Methods

Patients and clinical parameters
Clinical and pathological information available for 3,908 renal biopsy samples collected from 1997 to 2007 at the Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, was reviewed. The common feature was samples from patients aged older than 15 years of age at time of tissue harvest. The renal biopsies of all patients were examined by light microscopy (LM), electron microscopy (EM), and immunofluorescence (IF). The intended cases were selected from four patient groups: nonglomerulonephritis (non-GN), IgAN, BNS, and TMD. Patients in the non-GN group had no evidence of glomerulonephritis confirmed by LM, EM, and IF, and no systemic diseases. We regarded obese patients among the non-GN as ORG. IgAN represented mild mesangial proliferation as determined by LM. BNS was defined as renal changes associated with essential hypertension. TMD patients were those who had no clinical evidence of renal diseases except for micro/macrohematuria and histopathologically showed thin GBM (\250 nm) involving at least in 50% of GBM [12] . Patients with edema (e.g., nephrotic syndrome) and systemic disorders, such as diabetes mellitus, lupus nephritis, were excluded. The exclusion criteria of diabetes mellitus were titer of fasting blood glucose (FBG) lower than 120 mg/dL and no glucosuria. Obesity was defined as body mass index (BMI) C25 kg/m 2 , calculated as body weight (kg)/height 2 (m 2 ). According to the definition by the Japan Society for the Study of Obesity [13] , classification was assigned as follows; class 1 obesity, BMI C 25 but \30 kg/m 2 ; class 2 obesity, BMI C 30 but \35 kg/m 2 ; class 3 obesity, BMI C 35 but \40 kg/m 2 ; class 4 obesity, BMI C 40 kg/ m 2 . In this study, obese patients were divided into two obesity groups; mild obesity (class 1 obesity) and severe obesity (class 2, 3 and 4 obesity). Age-matched nonobese (BMI \ 25 kg/m 2 ) patients were also examined as controls in each group. Laboratory data were selected at time of renal biopsy. The study was approved by the Ethics Review Committee of Nagasaki University Graduate School of Biomedical Sciences.
Histological analysis
Histopathological lesions of the glomeruli were evaluated on LM sections stained with periodic acid-Schiff (PAS) and periodic acid silver-methenamin (PAM). Histopathological evaluation was performed on the index of glomerular lesion (IGL), which was modified by the methods of Stahl et al. [14] . IGL was evaluated by both proliferative and sclerotic changes. In addition, glomerular sclerosis was also scored as follows. Score of focal segmental glomerulosclerotic lesion (FSGS lesion score, %) was calculated as percentage of FSGS lesion. Global sclerotic glomeruli score (SG score, %) was calculated as percentage of global sclerotic glomeruli.
Measurement of glomerular diameter was conducted under LM and measured by WinRoof version 5.03 (Mitani Corp, Tokyo, Japan). Mean glomerular size was calculated from average of largest five glomerular diameters (lm) per case to approximate glomerular equatorial section 2 . The size (lm 2 ) was calculated as [(diameter/2) 2 9 3.14]. EM photographs at original magnification of 3,0009 were used to determine the thickness of the GBM using the technique described by Osawa et al. [15] .
Statistical analysis
All data were expressed as mean ± standard deviation (SD). Differences were performed by one-way analysis of variance (ANOVA), unpaired Student's t test, and Fisher's exact test. Statistical significance was defined as P \ 0.05. All statistical analyses were performed using SPSS 16.0J software for Windows (SPSS Inc., Chicago, IL). Table 1 summarizes the clinical and laboratory findings of the patients. Urinary protein was greater in obese patients of the non-GN, IgAN and BNS groups than in nonobese group, respectively, but severity of proteinuria did not correlate with extent of obesity. None of the TMD patients had severe . Titers of serum creatinine and blood urea nitrogen (BUN) were not significantly different between obese and nonobese groups. In non-GN group, blood pressure, triglyceride, and total cholesterol were significantly higher in obese groups than nonobese group. In IgAN and TMD, triglyceride was also significantly higher in obese patients. In TMD, blood pressure was higher in obese group than in nonobese group. Estimated glomerular filtration rate (eGFR) was lower in obese than in nonobese patients in non-GN group, but statistically significant difference was present only between nonobese and mildly obese patients. No difference was noted in eGFR level among nonobese and obese patients in IgAN, BNS or TMD groups. Percentage of cases with eGFR level lower than 60 mL/min/1.73 m 2 was higher in obese than in nonobese patients in IgAN and BNS, but not statistically significantly so. Data are mean ± SD BNS benign nephrosclerosis, TMD thin basement membrane disease, Score of FSGS lesion focal segmental glomerulosclerosis lesion scores, SG score global sclerotic glomeruli and/or hyalinized glomeruli score, score of FSGS lesion, and SG score were calculated in specimens with lesions Tables 2 and 3 show the scores assigned to histological features of nonobese and obese groups. Non-GN group: FSGS lesions were not seen in nonobese (Fig. 1a) or mild obesity groups. Two (20%) patients of the severe obesity group showed FSGS lesion (Fig. 1b) . Scores of IGL and FSGS lesion were higher in severe-obesity group than in nonobese and mild-obesity groups (Table 2) .
Results
Clinical features
IgAN group: The IGL was significantly higher in severe-obesity group than nonobese and mild-obesity group. There were no differences in score of FSGS lesion and SG scores among nonobese and obese groups. FSGS lesion and SG were observed in IgAN ( Fig. 1d; Table 2 ). BNS group: The IGL, score of FSGS lesion, and SG scores were not different between obese and nonobese groups. Although incidence of SG was high in patients with BNS, FSGS lesion was noted in only one nonobese patient and one severely obese patient ( Fig. 1e, f ; Table 3 ).
TMD group: None of the patients of the TMD group had severe obesity. In TMD group, there were no significant differences in IGL, score of FSGS lesion or SG scores between obese and nonobese groups (Table 3) . Only one obese patient had FSGS lesion and another one had two sclerotic glomeruli.
Glomerular size
Glomerular sizes of all groups are shown in Fig. 2 . In non-GN, the glomerular size of mild and severe obesity groups was significantly larger than that of the nonobese group. The proportion of cases with large glomeruli tended to be higher in mild-obesity than severe-obesity group, although the difference was not statistically significant. In IgAN, glomerular size was significantly greater in obese patients than in nonobese patients, and correlated with severity of obesity (Fig. 1c, d) . In BNS group, glomerular size was larger in obese than in nonobese groups, but the difference was not statistically significant. On the other hand, glomerular size was significantly greater in nonobese BNS than nonobese non-GN subjects ( Fig. 2; Table 3 ). Obesity was categorized as mild in all patients of the TMD group. Glomerular size of TMD was slightly, but not statistically significantly, larger in obese than in nonobese patients.
Comparison of nonobese patients showed that glomerular size was significantly greater in TMD than in non-GN subjects, in spite of compatible blood pressure levels (Figs. 1g, h, 2) .
Thickness of glomerular basement membrane
The results of measurement of GBM by EM observation are shown in Fig. 4 . GBM was thicker in obese patients than non-GN, and varied proportionately with severity of obesity (Figs. 3a, 4) (P \ 0.05, nonobese versus severe obesity). In IgAN, the GBM was slightly thicker in mildobesity group than nonobese group, though the difference was not statistically significant. Basement membrane in patients with IgAN was thin in some areas, in association with thick GBM (Fig. 3c, d ). In BNS, GBM was significantly ticker in mild-obesity group than in nonobese group (P \ 0.05) (Fig. 3g, h ). In TMD, there was no significant difference in GBM thickness between obese and nonobese groups (Fig. 3g, h ).
Discussion
In the present study, to observe the influence of obesity in patients with CKD, we selected patients with mild structural changes: mild forms of IgAN, BNS, and TMD. The obese patients of the nonglomerulonephritis group in our study had ORG. To our knowledge, this is the first report of the pathological influence of obesity on CKD, focusing on GBM thickness and obesity level.
Histopathological analysis identified glomerulomegaly and FSGS lesion in ORG patients, thus confirming previous findings [4] . In particular, FSGS lesion was observed in patients with severe obesity, and IGL score varied according to severity of obesity. Thickness of GBM was proportionate to severity of obesity in ORG. Kambham et al. [2] reported focal GBM thickening in ORG patients. A recent ultrastructural study of ORG showed widening of the foot processes and enlargement of podocytes in extremely obese patients, in addition to marked thickening of GBM [11] . The mechanisms of obesity-induced glomerulomegaly and GBM thickening are not completely understood. Obesity-associated humoral factors such as hyperinsulinemia and hyperleptinemia might increase transforming growth factor-b, vascular endothelial growth factor, and angiotensin II [1, 2] , stimulating overproduction of extracellular matrix. Therefore, glomerulomegaly [2] and GBM thickening [1, 16] were consequently developed. Wu et al. [17] showed that these factors were increased in ORG patients. Based on the above reports and the present study, it is concluded that obesity seems to influence GBM thickness in ORG with subsequent development of abnormalities, which probably depends on severity and duration of obese state. Hypertension is thought to be an important factor for progression of renal disease in ORG [1] . The effects of mild obesity were not present in IGL and FSGS lesion in mildobesity groups. However, some clinical parameters, such as eGFR, proteinuria and diastolic blood pressure (DBP), were worse in mild-obesity than in nonobese group in non-GN. This may reflect glomerular enlargement and GBM thickening. In our study, systemic blood pressure and thickness of GBM worsened with severity of obesity. It is possible that thickening of GBM is related to increased intraglomerular pressure in such patients [1, 18] . A few studies on obesity in IgAN have been reported [4, 19] . When obesity accompanies IgAN, pathological changes were more severe and proteinuria was grater [4] . However, there are only a few ultrastructural studies on the effect of obesity in IgAN; for example, Tanaka et al. [19] reported greater GBM thickening and larger total glomerular tuft areas in obese IgAN than in lean IgAN patients. Our data also showed significantly larger glomeruli in obese IgAN than in nonobese IgAN. Although the thickness of GBM in obese patients was slightly larger than that in nonobese patients, no significant difference was noted. EM showed areas of thin GBM in most patients with IgAN. This could explain the lack of statistical significance in terms of GBM thickness. IGL was higher in patients with severe obesity. Considered together, these results indicate that glomerular changes seem to be enhanced in IgAN obese patients, similar to in ORG patients.
Many studies have analyzed the relationships among BMI and blood pressure with glomerular lesions in ORG patients [5, 6, 20, 21] . In hypertensive patients, increased renal tubular sodium reabsorption and glomerular hyperfiltration may cause glomerulomegaly [1] . Fewer and larger glomeruli were described in hypertensive patients than in nonhypertensives [22, 23] . In our study, the glomeruli were larger in size in nonobese BNS group than in nonobese non-GN and IgAN groups. This change may be caused by intraglomerular hypertension and compensatory hypertrophy of the few glomeruli present in the kidney. Furthermore, the GBM was significantly thicker in obese BNS group than in nonobese group. Although glomerular injury was caused by hemodynamic abnormalities in BNS, obesity per se could accelerate glomerular lesions.
TMD is known to be associated with excellent prognosis, and is clinically called benign familial hematuria [12] . Many reports are available on ultrastructural changes in TMD, as well as the mechanism of the thin GBM. These studies emphasized that the only significant change in TMD is mild glomerulopathy, including thinning of GBM [24] . Interestingly, the glomeruli were significantly larger in size in obese TMD group than in nonobese non-GN and IgAN groups. The cause of glomerulomegaly in TMD is not clear at present; however, the lumen of glomerular capillaries may easily expand in presence of high intraglomerular pressure and abnormally thin GBM. None of the patients in the TMD group were severely obese. However, GBM may be thicker in severely obese TMD patients. Further studies are necessary to examine the effects of GBM thickening in obese TMD patients, including immunohistochemical examination of subunits of collagen type IV [12] .
In conclusion, the results of the present study indicate that obesity worsens urinary protein excretion and glomerular damage in patients with IgAN, BNS, and TMD. In addition, hypertension might be an important factor that precipitates renal disease in obesity-related nephropathy. In patients with CKD, obesity might worsen proteinuria and renal structural changes, similar to obesity-related nephropathy. In other words, obesity might promote progression of CKD. 
